In patients with myelodysplastic syndromes response to rHuEPO and G‐CSF treatment is related to an increase of cytogenetically normal CD34+ cells
- 19 July 2004
- journal article
- clinical trial
- Published by Wiley in British Journal of Haematology
- Vol. 126 (4) , 501-507
Abstract
The in vivo effect of recombinant human erythropoietin (rHuEpo) and granulocyte colony-stimulating factor (G-CSF) combined treatment on CD34(+) cells was evaluated by fluorescence in situ hybridization (FISH) in 13 myelodysplastic syndrome (MDS) patients with known cytogenetic abnormalities. After treatment, responsive patients presented a significantly lower proportion of FISH abnormal CD34(+) cells than before treatment (P = 0.003), and in comparison with unresponsive cases (P = 0.007). Response to treatment was associated with a reduced degree of apoptosis in CD34(+) cells (P = 0.021): however, no difference in telomere length was observed in responsive patients after growth factor administration. Although the number of patients analysed was relatively small, the present data suggest that, in MDS patients, response to rHuEpo and G-CSF may be related to the proliferation of karyotypically normal but potentially defective CD34(+) progenitor cells.Keywords
This publication has 34 references indexed in Scilit:
- A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of lifeBritish Journal of Haematology, 2003
- Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitorsBlood, 2003
- The World Health Organization (WHO) classification of the myeloid neoplasmsBlood, 2002
- The aging of lympho-hematopoietic stem cellsNature Immunology, 2002
- Sustained trilineage recovery and disappearance of abnormal chromosome clone in a patient with myelodysplastic syndrome following combination therapy with cytokines (granulocyte colony-stimulating factor and erythropoietin) and high-dose methylprednisoloneBritish Journal of Haematology, 1996
- Response of myelodysplastic syndrome marrow progenitor cells to stimulation with cytokine combinations in a stroma‐free long‐term culture systemBritish Journal of Haematology, 1996
- Photomultiplier voltage setting: Possible important source of variability in molecular equivalents of soluble fluorochrome (MESF) calculation?Cytometry, 1995
- Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: A clinical and erythrokinetic assessmentAnnals of Hematology, 1992
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982